Audentes Therapeutics Inc (NASDAQ:BOLD) marked the Rare Disease Day by unveiling the benevolent ‘Be Bold for Courageous Patients’ program. The program aims at supporting families and individuals living with a rare disease. Despite this kind gesture to patients suffering from rare genetic diseases, the company’s stock nose-dived during the previous trading session closing at a disappointing $32.26 from an opening price of $34.94. The company’s market value took a hit as well settling at $1.41 billion.

The ‘Be Bold for Courageous patients’ stamps the company’s commitment to Rare Disease patients and families.

Sponsored Events

Audentes has endeavored to give a sponsorship grant that will be used to support children living with rare diseases attend the Painted Turtle and Double H Ranch, Medical specialty camps. These camps and events provide these kids with an opportunity of a lifetime to enjoy themselves in a special environment designed to meet their needs.

As of March 1-3, children will attend the Painted Turtle in Lake Hughes, California. Alternatively, they can attend the Double H Ranch from June 7-11 during the camp inspiration for BIBAP kids. At these specialized camps, children can play, sing, and have all sorts of fun while discovering their potential. Audentes employees will get a day off to volunteer at the Neuromuscular and Genetic Family Weekend and Camp Inspiration.

Management’s thoughts

Matthew R. Patterson, Chairman, and CEO, Audentes speaking during the launch of the program said that, we are pleased to launch ‘Be Bold for Courageous Patients’ to further serve the needs of the rare disease community in unique and positive ways, including teaming up with The Painted Turtle and Double H Ranch.”

Chris Butler, The Painted Turtle Chief Executive Office applauded Audentes’ move to sponsor children for the Painted Turtle event. The ‘Be Bold for Courageous Patients’ Program seeks to fund rare disease work. Audentes will give grants and contributions to help research on rare diseases. Through the program, Audentes seeks to have a meaningful impact on the rare disease community. Also through the program, Audentes will inspire its employees to volunteer and show commitment for the patients.

Looking for the next Pfizer (PFE) or Johnson&Johnson (JNJ)? Take advantage of Kyle Dennis’ free biotech trader’s handbook and how he made his first $2.9 Million in the market. The smart money is pouring into this sector and you’ll want to grab a piece of this action! Which company is next to explode?